Survivorship in der Onkologie: Psychosoziale Folgen bei Krebsüberlebenden

Zusammenfassung

Die Zahl der Menschen, die mit oder nach einer Krebserkrankung leben, nimmt aufgrund unserer alternden Gesellschaft und einer verbesserten Krebsbehandlung stetig zu. Nach abgeschlossener Therapie bleiben jedoch oft Folgen der Erkrankung lange spürbar und beeinflussen Betroffene noch Jahre später, was zu hohem Leidensdruck und Versorgungsbedarf führt. Eine psychoonkologische Begleitung bietet eine wirksame Unterstützung für Spät- und Langzeitfolgen.

Schlüsselwörter

Psychosoziale Folgen - Krebsüberlebende - Psychoonkologie - Angst - Depression - Fatigue

Publication History

Article published online:
04 December 2023

• Literatur

• 1 Erdmann F, Spix C, Katalinic A. et al. Krebs in Deutschland für 2017/2018. Berlin: Robert Koch-Institut; 2021
• 2 Bloom JR, Petersen DM, Kang SH. Multi-dimensional quality of life among long-term (5+years) adult Cancer Survivors. Psycho-Oncology 2007; 16: 691-706 DOI: 10.1002/pon.1208.
• 3 Schaapveld M, Aleman BMP, van Eggermond AM. et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. New Engl J Med 2015; 373: 2499-2511 DOI: 10.1056/NEJMoa1505949.
• 4 Mehnert A, Koch U. Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. Psycho-Oncology 2007; 16: 181-188 DOI: 10.1002/pon.1057.
• 5 Mehnert A, Hartung TJ, Friedrich M. et al. One in two cancer patients is significantly distressed: Prevalence and indicators of distress. Psycho-Oncology 2018; 27: 75-82 DOI: 10.1002/pon.4464.
• 6 Andersen BL, DeRubeis RJ, Berman BS. et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: An American Society of Clinical Oncology Guideline adaptation. J Clin Oncol 2014; 32: 1605-1619 DOI: 10.1200/JCO.2013.52.4611.
• 7 Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Int Med 2001; 16: 606-613 DOI: 10.1046/j.1525-1497.2001.016009606.x.
• 8 Spitzer RL, Kroenke K, Williams JBW. et al. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Int Med 2006; 166: 1092-1097 DOI: 10.1001/archinte.166.10.1092.
• 9 Mehnert A, Müller D, Lehmann C. et al. Die deutsche Version des NCCN Distress-Thermometers. Z Psychiatr. Psychol Psychother 2006; 54: 213-223 DOI: 10.1024/1661-4747.54.3.213.
• 10 Jacobsen PB, Donovan KA, Trask PC. et al. Screening for psychologic distress in ambulatory cancer patients. Cancer 2005; 103: 1494-1502 DOI: 10.1002/cncr.20940.
• 11 Mitchell AJ, Chan M, Bhatti H. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 2011; 12: 160-174 DOI: 10.1016/S1470-2045(11)70002-X.
• 12 Hartung TJ, Brähler E, Faller H. et al. The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. Eur J Cancer 2017; 72: 46-53 DOI: 10.1016/j.ejca.2016.11.017.
• 13 Henry DH, Viswanathan HN, Elkin EP. et al. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Supp Care Cancer 2008; 16: 791-801 DOI: 10.1007/s00520-007-0380-2.
• 14 Götze H, Friedrich M, Taubenheim S. et al. Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis. Supp Care Cancer 2020; 28: 211-220 DOI: 10.1007/s00520-019-04805-1.
• 15 Koch L, Jansen L, Brenner H. et al. Fear of recurrence and disease progression in long-term (≥5 years) Cancer Survivors – a systematic review of quantitative studies. Psycho-Oncology 2013; 22: 1-11 DOI: 10.1002/pon.3022.
• 16 Brintzenhofe-Szoc KM, Levin TT, Li Y. et al. Mixed anxiety/depression symptoms in a large cancer cohort: Prevalence by cancer type. Psychosomatics 2009; 50: 383-391 DOI: 10.1176/appi.psy.50.4.383.
• 17 Hinz A, Mehnert A, Dégi C. et al. The relationship between global and specific components of quality of life, assessed with the EORTC QLQ-C30 in a sample of 2019 cancer patients. Eur J Cancer Care 2017; 26: e12416 DOI: 10.1111/ecc.12416.
• 18 Abbey G, Thompson SBN, Hickish T. et al. A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder. Psycho-Oncology 2015; 24: 371-381 DOI: 10.1002/pon.3654.
• 19 Mehnert A, Vehling S, Scheffold K. et al. Prävalenz von Anpassungsstörung, Akuter und Posttraumatischer Belastungsstörung sowie somatoformen Störungen bei Krebspatienten. Psychother Psychosom Med Psychol 2013; 63: 466-472 DOI: 10.1055/s-0033-1347197.
• 20 Schover LR, van der Kaaij M, van Dorst E. et al. Sexual dysfunction and infertility as late effects of cancer treatment. Eur J Cancer 2014; 12: 41-53 DOI: 10.1016/j.ejcsup.2014.03.004.
• 21 Heyne S, Esser P, Geue K. et al. Frequency of sexual problems and related psychosocial characteristics in cancer patients – findings from an epidemiological multicenter study in Germany. Front Psychol 2021; 12: 679870 DOI: 10.3389/fpsyg.2021.679870.
• 22 Ljungman L, Ahlgren J, Petersson L-M. et al. Sexual dysfunction and reproductive concerns in young women with breast cancer: Type, prevalence, and predictors of problems. Psycho-Oncology 2018; 27: 2770-2777 DOI: 10.1002/pon.4886.
• 23 Berger AM, Mooney K, Alvarez-Perez A. et al. Cancer-related fatigue, Version 2.2015. J Natl Compr Canc Netw 2015; 13: 1012-1039 DOI: 10.6004/jnccn.2015.0122.
• 24 Bower JE. Cancer-related fatigue – mechanisms, risk factors, and treatments. Nature Rev Clin Oncol 2014; 11: 597-609 DOI: 10.1038/nrclinonc.2014.127.
• 25 Pachman D, Barton D, Swetz K. et al. Troublesome symptoms in cancer survivors: Fatigue, insomnia, neuropathy, and pain. J Clin Oncol 2012; 30: 3687-3696 DOI: 10.1200/JCO.2012.41.7238.
• 26 van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ. et al. Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. J Pain Sympt Manag 2016; 51: 1070-1090.e9 DOI: 10.1016/j.jpainsymman.2015.12.340.
• 27 Porter LS, Keefe FJ. Psychosocial issues in cancer pain. Curr Pain Headache Rep 2011; 15: 263-270 DOI: 10.1007/s11916-011-0190-6.
• 28 Bennedsgaard K, Ventzel L, Themistocleous AC. et al. Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy. Cancer Med 2020; 9: 5114-5123 DOI: 10.1002/cam4.3129.
• 29 Seretny M, Currie GL, Sena ES. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. PAIN 2014; 155: 2461-2470 DOI: 10.1016/j.pain.2014.09.020.
• 30 Janelsins MC, Kesler SR, Ahles TA. et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatr 2014; 26: 102-113 DOI: 10.3109/09540261.2013.864260.